Phenazopyridine
Based on 2 publication(s) in Google Scholar
Phenazopyridine is a competitive SARM1 inhibitor, with IC50 145 μM. Phenazopyridine is a TRPM8 antagonist. Phenazopyridine has a local anesthetic/analgesic effect. Phenazopyridine is used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine can promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 94-78-0
- Formula: C11H11N5
- Molecular Weight:213.24
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mechanoreceptors Compound Library
HY-L095
-
Inactive Ingredient Library
HY-L096
-
Tumorigenesis-Related Compound Library
HY-L100
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Nephrotoxicity Compound Library
HY-L229
Publications Citing Use of MedChemExpress (MCE) Phenazopyridine
More
Biological Activity
EC50: 145 μM (SARM1)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BHK-21 | CC50 |
>20 μM
Compound: 64
|
cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay
cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay
|
[PMID: 32845145] |
| LLC-MK2 | CC50 |
>20 μM
Compound: 64
|
Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay
Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay
|
[PMID: 32845145] |
| Vero | CC50 |
>50 μM
Compound: Phenazopyridine
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
28 μM
Compound: Phenazopyridine
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
Phenazopyridine (10-30 μM; 12 h) increases mRNA expression of RPS23RG1 in both human SHSY5Y and mouse N2a cells[2].
Phenazopyridine (5-50 μM; 2 min) inhibits menthol induced (50 μM) TRPM8 response in a dose-dependent and reversible manner in HEK293 cells with an IC50 of 9.6 μM[4].
Phenazopyridine hydrochloride(3 μM; 6 weeks) can promote neuronal differentiation in human embryonic stem cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human ES cells
-
Concentration:3 μM
-
Incubation Time:6 weeks
-
Result:After 10 weeks formed a neural network in the cells.
-
Cell Line:Human ES cells
-
Concentration:3 μM
-
Incubation Time:6 weeks
-
Result:Accelerated emergence of early neuronal markers and decreased markers of undifferentiated and non-neural cells.
Phenazopyridine (0.1-3 mg/kg; i.v.; Single dose) can inhibit mechanosensitive Aδ- fibers, but has no inhibitory effect on C-fibers in Sprague - Dawley rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice model of Alzheimer's disease< sup>[2]
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection (i.p.); Once daily for 2 weeks
-
Result:Increased the RPS23RG1 levels in lungs, liver and kidneys of mice.
-
Animal Model:APP/PS1 mice model of Alzheimer's disease[2]
-
Dosage:15 mg/kg
-
Administration:Intracerebroventricularly injection; Once daily for 2 weeks
-
Result:Significantly reduced amyloid plaques.
Increased protein levels of RPS23RG1, PSD-95, and phosphorylated/inactivated GSK-3β, though without affecting levels of tau, phosphorylated tau, and p35.
Chemical Information
-
CAS No. 94-78-0
-
Appearance Solid
-
Molecular Weight 213.24
-
Formula C11H11N5
-
Color Yellow to orange
-
SMILES
NC1=NC(N)=CC=C1/N=N/C2=CC=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Neuropsychopharmacology
Phenazopyridine promotes RPS23RG1/Rps23rg1 transcription and ameliorates Alzheimer-associated phenotypes in mice. [Abstract]2022 Nov;47(12):2042-2050. PMID: 35821069 -
EMBO Rep
2022 Jun 7;23(6):e53932. PMID: 35403787
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Loring H S, et al. Identification of the first noncompetitive SARM1 inhibitors[J]. Bioorganic & Medicinal Chemistry, 2020, 28(18): 115644. [Content Brief]
[2]. Wang C, et al. Phenazopyridine promotes RPS23RG1/Rps23rg1 transcription and ameliorates Alzheimer-associated phenotypes in mice[J]. Neuropsychopharmacology, 2022, 47(12): 2042-2050. [Content Brief]
[3]. Aizawa N, et al. Effects of phenazopyridine on rat bladder primary afferent activity, and comparison with lidocaine and acetaminophen[J]. Neurourology and Urodynamics, 2010, 29(8): 1445-1450. [Content Brief]
[4]. Luyts N, et al. Inhibition of TRPM8 by the urinary tract analgesic drug phenazopyridine[J]. European Journal of Pharmacology, 2023, 942: 175512. [Content Brief]
[5]. Suter, David M et al. Phenazopyridine hydrochlorideinduces and synchronizes neuronal differentiation of embryonic stem cells. Journal of cellular and molecular medicine vol. 13,9B (2009): 3517-27. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz